Review
Version 1
Preserved in Portico This version is not peer-reviewed
Viral-Vector Delivered anti-Angiogenic Therapies to the Eye
Version 1
: Received: 22 December 2020 / Approved: 23 December 2020 / Online: 23 December 2020 (17:45:44 CET)
How to cite: Koponen, S.; Kokki, E.; Kinnunen, K.; Ylä-Herttuala, S. Viral-Vector Delivered anti-Angiogenic Therapies to the Eye. Preprints 2020, 2020120602 (doi: 10.20944/preprints202012.0602.v1). Koponen, S.; Kokki, E.; Kinnunen, K.; Ylä-Herttuala, S. Viral-Vector Delivered anti-Angiogenic Therapies to the Eye. Preprints 2020, 2020120602 (doi: 10.20944/preprints202012.0602.v1).
Abstract
Pathological vessel growth harms vision and may finally lead to vision loss. Anti-angiogenic gene therapy with viral vectors for ocular neovascularization has shown great promise in pre-clinical studies. Most of the studies has conducted with different adeno-associate serotype vectors. In addition, Adeno and lentivirus vectors have been used. Therapy has targeted to block vascular endothelial growth factors or other pro-angiogenic factors. Clinical trials of intraocular gene therapy for neovascularization have shown the treatment to be safe without severe adverse events or systemic effects. Nevertheless, clinical studies have not proceeded phase 2 trials further.
Subject Areas
Gene therapy; ocular neovascularization; viral vectors; preclinical; clinical trials; anti-angiogenesis; AAV
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)